Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil in CAD Patients on Hemodialysis
NCT01475123Phase 4Active, not recruiting
- Sponsor
- Kumamoto University
- Start
- Jun 2008
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicorandil in coronary artery disease (CAD) (2 arms), sponsored by Kumamoto University. Primary endpoint: Composite of cardiovascular death, sudden cardiac death, nonfatal myocardial infarction, hospitalization for recurrent symptomatic myocardial ischemia and stroke at 2 years. Started Jun 2008; status: active, not recruiting.
02
Drugs
nicorandil
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01475123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01475123.